Jinxin Fertility Group (JXFGF) Fair Value & Analysis
Healthcare · US · Market cap $745M
Analysis
Jinxin Fertility Group (JXFGF) currently trades at $0.2900, while our model-based Fair Value estimate is $0.2200 — implying the stock looks roughly 24.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and internationally. The company provides two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; obstetrics, gynecology, urology, internal medicine, and pediatrics medical services; ambulatory surgery center facilities services; and ancillary medical services. Further, it provides pre-implantation genetic screening testing, management consultancy, postpartum and rehabilitation care, maternal-child nursing, and other hospital- derived services. Additionally, t…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.